Bristol’s $74 Billion Celgene M&A Likely Gains Quick EU Approval
(Premium) – Bristol-Myers Squibb’s proposed $74 billion acquisition of Celgene is likely to get a phase one approval in Europe, though requirements of small divestitures can’t be ruled out. The companies’ overlap in broad segments won’t raise antitrust concerns.
Continue Reading